var data={"title":"Lipoprotein glomerulopathy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Lipoprotein glomerulopathy</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/contributors\" class=\"contributor contributor_credentials\">Takao Saito, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/contributors\" class=\"contributor contributor_credentials\">Richard J Glassock, MD, MACP</a></dd><dd><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/contributors\" class=\"contributor contributor_credentials\">Brad H Rovin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/contributors\" class=\"contributor contributor_credentials\">Albert Q Lam, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 03, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lipoprotein glomerulopathy (LPG) is a unique and rare disorder of renal lipidosis that was first reported in a Japanese patient in 1989 [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/1\" class=\"abstract_t\">1</a>]. It is characterized by lipoprotein thrombi in glomeruli, an abnormal plasma lipoprotein profile that resembles type III hyperlipoproteinemia, and a marked increase in serum apolipoprotein E (apo E) concentrations. LPG was subsequently found to be due to mutations of the <em>APOE</em> gene [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2\" class=\"abstract_t\">2</a>]. However, intrinsic renal factors are also involved in the pathogenesis of LPG because of the incomplete penetrance based upon many asymptomatic carriers of <em>APOE</em> variants [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/3-5\" class=\"abstract_t\">3-5</a>].</p><p>A review of the clinical features of LPG is presented in this topic review.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initial reports of familial cases as well as recurrence in transplanted kidneys suggested that a systemically acting genetic factor may underlie LPG. It was also observed that the serum apo E isoform was inconsistent with the <em>APOE</em> genotype among affected individuals.</p><p>These findings predicted that an uncharacterized variant(s) of the <em>APOE</em> gene may be responsible for the pathogenesis of this disorder [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/6\" class=\"abstract_t\">6</a>]. This was subsequently confirmed as mutations in the <em>APOE</em> gene have been found in all reported cases of LPG in which DNA sequencing has been performed (<a href=\"image.htm?imageKey=NEPH%2F59528\" class=\"graphic graphic_algorithm graphicRef59528 \">algorithm 1</a>).</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">APOE variants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Apolipoprotein E (apo E), an essential apolipoprotein, is a major constituent of various plasma lipoproteins. Plasma lipoprotein levels are determined in part by the binding activities of apo E to the LDL receptor, LDL receptor-related protein, and VLDL receptor. Apo E is composed of 299 amino acids and has a relative molecular mass of 34kDa.</p><p>A number of serum isoforms of apo E have been described. They differ based upon their migration properties as determined by isoelectric focusing polyacrylamide gel electrophoresis (IEF). The most common serum apo E isoform is apo E3.</p><p>Observations in patients with type III hyperlipoproteinemia provided insight into the pathogenesis of LPG. Type III hyperlipoproteinemia is a multifactorial disorder that is characterized by the presence of two apo E2 alleles. It is also occasionally associated with renal lipidosis showing sclerosis and foam cells in the glomerulus [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/7-9\" class=\"abstract_t\">7-9</a>].</p><p>Among affected individuals with LPG (which is directly associated with renal lipidosis), the serum apo E isoform was noted to be inconsistent with the <em>APOE</em> genotype. This suggested that an uncharacterized variant(s) of the <em>APOE</em> gene may underlie the pathogenesis of this disorder [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/6\" class=\"abstract_t\">6</a>].</p><p>Subsequently, mutations of the <em>APOE</em> gene have been described in all patients with LPG in whom DNA sequencing has been performed [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2,3,10\" class=\"abstract_t\">2,3,10</a>], except for the cases in one report from China [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/11\" class=\"abstract_t\">11</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In most cases from the eastern part of Japan, DNA sequence analysis of the <em>APOE</em> gene reveal a nucleotide substitution of G to C at codon 145 [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/6\" class=\"abstract_t\">6</a>]. This missense mutation results in an amino acid substitution of the proline residue for arginine residue at position 145 of apo E, and was termed apo E Sendai (<a href=\"image.htm?imageKey=NEPH%2F70954\" class=\"graphic graphic_figure graphicRef70954 \">figure 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another major mutation called apo E Kyoto is found world-wide in various races, including Japanese, Chinese and Caucasian [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/12-17\" class=\"abstract_t\">12-17</a>]. This mutation changes the amino acid at position 25 of apo E from arginine to cysteine. This position is not directly related to the central portion (position 136 to 158) of apo E, which is involved in binding to the LDL receptor. However, the removal of arginine at 25 could break the tertiary structure of apo E, as well as the change at 145 in apo E Sendai [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Several other apo E variants have been found in LPG patients (<a href=\"image.htm?imageKey=NEPH%2F70954\" class=\"graphic graphic_figure graphicRef70954 \">figure 1</a>). Some are missense mutations [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/13,16,18-22\" class=\"abstract_t\">13,16,18-22</a>], while others are in-frame deletions [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/23-25\" class=\"abstract_t\">23-25</a>]. As a whole, more than 10 different causative <em>APOE</em> mutations associated with LPG have been reported [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/26\" class=\"abstract_t\">26</a>]. </p><p/><p>Most mutations detected in patients with LPG are found in <span class=\"nowrap\">and/or</span> around the LDL receptor binding domain (<a href=\"image.htm?imageKey=NEPH%2F70954\" class=\"graphic graphic_figure graphicRef70954 \">figure 1</a>). In particular, the substitutions of proline, eg, apo E Sendai [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/6\" class=\"abstract_t\">6</a>], apo E Chicago [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/27\" class=\"abstract_t\">27</a>], apo E Guangzhou [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/20\" class=\"abstract_t\">20</a>] and apo E <span class=\"nowrap\">Osaka/Kurashiki</span> [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/28,29\" class=\"abstract_t\">28,29</a>], are important mutations because they may produce severe structural changes in the middle of the alpha-helix, thereby altering the three-dimensional conformation of the protein [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/6\" class=\"abstract_t\">6</a>]. It is hypothesized that the abnormal lipoproteins aggregate and then deposit in the glomerular capillary walls <span class=\"nowrap\">and/or</span> around the mesangium, with subsequent transformation into lipoprotein thrombi.</p><p>In vitro studies and murine models of LPG support the view that apo E variants are directly responsible for these glomerular lesions [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/10\" class=\"abstract_t\">10</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LPG results after transduction of the apo E Sendai variant into mice with genetic deletion of the wild type <em>APOE</em> gene [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/30,31\" class=\"abstract_t\">30,31</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In vitro studies reveal that the apo E Sendai variant lipoprotein has reduced affinity for the low-density lipoprotein (LDL) receptor [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/32\" class=\"abstract_t\">32</a>]. This decreased binding ability is shared with the apo E2 allele found in patients with familial type III hyperlipoproteinemia [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/33-35\" class=\"abstract_t\">33-35</a>], which is also sometimes associated with renal lipidosis [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/7-9\" class=\"abstract_t\">7-9</a>].</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Role of other factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Despite the evidence in favor of a causative role for apo E variants in LPG, several observations suggest that additional factors are involved in the induction of LPG. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are asymptomatic carriers of apo E variants in families with LPG.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LPG-like lesions do not develop in all apo E Sendai transfected mice.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LPG-like lesions have been observed in mice with hyperlipidemia and genetic deletion of the <em>APOE</em> genes [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/36,37\" class=\"abstract_t\">36,37</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lesions are confined to the glomeruli of LPG, suggesting that unique intrinsic glomerular factors found in the affected host interact with apo E variants.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cases of LPG sometimes occur in association with other glomerular diseases, eg, IgA nephropathy, membranous glomerulopathy, lupus nephritis [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p/><p>Macrophage impairment represented by Fc receptors (FcRs) may be one such non-apo E factor. FcRs mediate the uptake of immune complex- or C-reactive protein (CRP)-binding LDL into macrophages, thereby inducing phagocytosis and atherosclerosis with foam cells [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/38-40\" class=\"abstract_t\">38-40</a>]. In mice, FcR dysfunction can be induced by eliminating the FcR gamma chain, which is required to allow the surface expression and signal transduction of the receptor. In FcR gamma chain (FcR gamma) knockout mice, LPG-like lesions characterized by lipoprotein thrombi are found in glomeruli [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/41\" class=\"abstract_t\">41</a>]. The lack of scavenger receptors induced by FcR dysfunction may suppress the uptake of lipids by macrophages and contribute to form lipoprotein thrombi [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/42\" class=\"abstract_t\">42</a>]. In addition, several studies in mice show the interaction between abnormal macrophage function and apo E in the pathogenesis of LPG [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/43,44\" class=\"abstract_t\">43,44</a>]. In one study, LPG-like changes are generated by injecting various apo E vectors in <em>APOE</em> and FcR gamma double knockout mice [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since the first published case in 1989, more than 150 cases of lipoprotein glomerulopathy (LPG) have been reported worldwide, and approximately 120 cases have been assayed by DNA sequencing (<a href=\"image.htm?imageKey=NEPH%2F105284\" class=\"graphic graphic_figure graphicRef105284 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/45\" class=\"abstract_t\">45</a>]. Most cases have been found in Japan and East Asian countries [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2\" class=\"abstract_t\">2</a>]. However, cases outside of Asia, such as the United States and Europe, have been identified [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/13,21,22,27,46-51\" class=\"abstract_t\">13,21,22,27,46-51</a>]. In the seven cases from the United States, four are of European ancestry [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/13,21,49\" class=\"abstract_t\">13,21,49</a>], two are of Asian ancestry [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/46,50\" class=\"abstract_t\">46,50</a>], and one is Mexican [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/27\" class=\"abstract_t\">27</a>]. Three Italian and two French cases are Caucasian [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/22,47,48\" class=\"abstract_t\">22,47,48</a>]. Cases from Russia and Brazil have also been reported [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/52,53\" class=\"abstract_t\">52,53</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with lipoprotein glomerulopathy (LPG) are asymptomatic. The average age is 32 years old, although the age at onset varies widely (ranging from 4 to 69 years [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2\" class=\"abstract_t\">2</a>]). The male to female ratio is approximately 3:2.</p><p>Affected patients usually come to medical attention after the detection of proteinuria on routine screening examination. Some patients present with symptoms and signs of the nephrotic syndrome.</p><p>Inheritance of LPG appears to be autosomal dominant with incomplete penetrance [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/3-5\" class=\"abstract_t\">3-5</a>]. Apo E Sendai [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/4\" class=\"abstract_t\">4</a>] and apo E Kyoto [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/5\" class=\"abstract_t\">5</a>] may have descended from a single founder.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Renal findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>At presentation, all patients with LPG have proteinuria of variable severity, ranging from mild to severe. Most eventually develop nephrotic syndrome or nephrotic-range proteinuria. The average urinary protein excretion of reported patients at time of renal biopsy is 4.8 grams per day (range of 0.3 to 18 <span class=\"nowrap\">grams/day)</span>. Microscopic hematuria is usually not observed.</p><p>Average creatinine clearance of patients is 90 <span class=\"nowrap\">mL/min</span> per 1.73 m<sup>2</sup> (range of 35 to 143 <span class=\"nowrap\">mL/min</span> per 1.73 m<sup>2</sup>) at the time of kidney biopsy. One-half of patients eventually develop end-stage renal disease at 1 to 27 years after disease onset [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2\" class=\"abstract_t\">2</a>]. On average, this occurs within approximately 7.5 years from time of diagnosis, as calculated by Kaplan-Meier's method.</p><p>In several cases, LPG has been associated with other glomerulopathies. These include IgA nephropathy, membranous nephropathy, and lupus nephritis [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Non-renal manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Characteristic non-renal symptoms appear to be limited:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In most cases, systemic manifestations, such as hypertension, atherosclerosis, cardiovascular change, and hepatic dysfunction, are mild. Among those with significant proteinuria, edema and decreased albumin levels are found.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical symptoms characteristic of lipidosis, such as corneal arcus, xanthoma, and Achilles tendon thickening, are rarely observed.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cases with psoriasis vulgaris have also been reported [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/54\" class=\"abstract_t\">54</a>].</p><p/><p>Despite comparatively high serum triglyceride levels, no cases of pancreatitis have been reported.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Lipid and lipoprotein profiles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with LPG have hyperlipidemia with a predominance of triglycerides. When isolated by ultracentrifugation, high cholesterol levels are observed in very low-density lipoprotein (VLDL) and intermediate density lipoprotein (IDL) fractions [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/55\" class=\"abstract_t\">55</a>]. Agarose gel electrophoresis for lipoprotein shows a broad beta band. These findings are consistent with type III hyperlipoproteinemia [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/56,57\" class=\"abstract_t\">56,57</a>]. (See <a href=\"topic.htm?path=hypertriglyceridemia\" class=\"medical medical_review\">&quot;Hypertriglyceridemia&quot;</a>.)</p><p>However, the increased levels of triglycerides and cholesterol in plasma are frequently less pronounced than patients with familial type III hyperlipoproteinemia and are even occasionally within normal ranges [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/23,58\" class=\"abstract_t\">23,58</a>]. Among reported patients, average plasma triglyceride and total cholesterol levels are 313 <span class=\"nowrap\">mg/dL</span> (range of 74 to 1019 <span class=\"nowrap\">mg/dL)</span> and 272 <span class=\"nowrap\">mg/dL</span> (range of 107 to 720 <span class=\"nowrap\">mg/dL),</span> respectively [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2\" class=\"abstract_t\">2</a>].</p><p>A high serum concentration of apo E is another characteristic finding in LPG. The average plasma apo E level is 17.1 <span class=\"nowrap\">mg/dL</span> (range of 3.9 to 71.0 <span class=\"nowrap\">mg/dL),</span> which is approximately twofold higher than the upper normal range [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2\" class=\"abstract_t\">2</a>].</p><p>In most cases, the <em>APOE</em> phenotype determined by isoelectric focusing polyacrylamide gel electrophoresis (IEF) shows heterozygosity for the E2 allele <span class=\"nowrap\">(E2/3</span> or <span class=\"nowrap\">E2/4)</span> [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/3\" class=\"abstract_t\">3</a>]; this differs from that of familial type III hyperlipoproteinemia, which is homozygous for E2. In some cases, however, the protein band by IEF is recognized at the position of E1 [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/23,24\" class=\"abstract_t\">23,24</a>] or between E2 and E3 [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/14,48\" class=\"abstract_t\">14,48</a>].</p><p>On the other hand, the <em>APOE</em> genotype routinely determined by restriction fragment length polymorphism analysis (RFLP) with restriction enzyme HhaI shows <span class=\"nowrap\">E3/3</span> or <span class=\"nowrap\">E3/4,</span> which is inconsistent with the <em>APOE</em> phenotype as determined by IEF [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Histopathologic findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Findings on renal biopsy include the following:</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Light microscopy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Light microscopic examination of renal biopsy material shows marked dilatation of the capillary lumen in the glomeruli by a pale-stained substance (<a href=\"image.htm?imageKey=NEPH%2F65560\" class=\"graphic graphic_picture graphicRef65560 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/1\" class=\"abstract_t\">1</a>]. Foam cells, which are characteristic of lipidosis, are rarely seen in either the glomeruli or the interstitium.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Electron microscopy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Electron microscopy shows that the thrombus-like substances in the glomerular capillaries are composed of granules and vacuoles of various sizes forming concentric lamellate like a fingerprint (<a href=\"image.htm?imageKey=NEPH%2F62285\" class=\"graphic graphic_picture graphicRef62285 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/3,59\" class=\"abstract_t\">3,59</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Confirmation of lipoprotein deposits</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Using snap-frozen kidney sections, immunofluorescence studies reveal deposition of apo B and apo E (<a href=\"image.htm?imageKey=NEPH%2F74959\" class=\"graphic graphic_picture graphicRef74959 \">picture 3</a>), and Sudan or oil-red O staining reveals lipid droplets in the thrombus-like substances (<a href=\"image.htm?imageKey=NEPH%2F68230\" class=\"graphic graphic_picture graphicRef68230 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lipoprotein glomerulopathy (LPG) should be suspected in the patient who presents with proteinuria and dyslipidemia with a predominance of triglycerides. Initial evaluation includes lipoprotein and apo E tests and agarose gel electrophoresis. Findings consistent with LPG include increased plasma VLDL and IDL levels, a broad beta-band on agarose gel electrophoresis, and a high serum apo E level.</p><p>If this initial evaluation is consistent with LPG, we always obtain a renal biopsy and perform analysis of apo E phenotype and genotype. DNA sequence analysis is useful for the confirmation of diagnosis.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical elements most consistent with lipoprotein glomerulopathy (LPG) include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Proteinuria.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Type III hyperlipoproteinemia with high levels of VLDL and IDL plus increased apo E concentration [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/55-57\" class=\"abstract_t\">55-57</a>]. This is usually associated with a heterozygous <em>APOE</em> phenotype, <span class=\"nowrap\">E2/3</span> or <span class=\"nowrap\">E2/4,</span> by immunoelectrophoresis but sometimes with an uncommon type, eg, <span class=\"nowrap\">E1/3</span> or others.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Renal biopsy showing, on light microscopy, dilatation of glomerular capillary lumina with pale-stained substances and, on electron microscopy, stone- or sand-like granules occupying the capillary lumina.</p><p/><p>To establish the diagnosis, DNA sequence analysis of <em>APOE</em> should be conducted, if possible. <em>APOE</em> variants have been detected in all LPG patients in whom DNA sequence was determined. At present, DNA sequence analysis of <em>APOE</em> can be assayed in various commercial laboratories using blood samples.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A significant number of primary kidney diseases also present with significant proteinuria and renal dysfunction. Although analysis of lipoproteins and apolipoproteins may distinguish lipoprotein glomerulopathy (LPG) from these diseases clinically, the diagnosis is definitively obtained by renal biopsy. (See <a href=\"topic.htm?path=glomerular-disease-evaluation-and-differential-diagnosis-in-adults\" class=\"medical medical_review\">&quot;Glomerular disease: Evaluation and differential diagnosis in adults&quot;</a>.)</p><p>LPG is associated with segmental sclerosis of the glomerulus and mesangial interposition, findings also observed in focal segmental glomerulosclerosis and membranoproliferative glomerulonephritis, respectively. These disorders can be distinguished from LPG after DNA sequencing.</p><p>In several reports, familial type III hyperlipoproteinemia due to <em>APOE2</em> homozygosity has been associated with glomerulosclerosis, including foam cells [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/7-9,60\" class=\"abstract_t\">7-9,60</a>], and occasionally with LPG-like lesions such as lipoprotein thrombi [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/61,62\" class=\"abstract_t\">61,62</a>]. One case, with the combination of <em>APOE2</em> and <em><span class=\"nowrap\">APOE2-Tokyo/Maebashi</em></span> genes, showed both foam cells and lipoprotein thrombi, providing the relationship between histologic characteristics and <em>APOE</em> gene abnormalities [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/63\" class=\"abstract_t\">63</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no high-quality data that have established an effective therapeutic regimen for lipoprotein glomerulopathy (LPG). However, severe hypertriglyceridemia aggravates the features of LPG in both human cases and animal models. Accordingly, preventing hypertriglyceridemia may be an important aspect of treatment.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Specific therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lipid-lowering therapy consisting of different agents, either administered alone or in combination, have been examined:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In some case reports, intensive therapy using lipid-lowering agents including fibrates resulted in clinical remission with histological resolution [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/19,64-66\" class=\"abstract_t\">19,64-66</a>]. These cases reported reductions in serum cholesterol, triglycerides and apo E levels and complete disappearance of lipoprotein thrombi in serial renal biopsies.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one controlled study, the three-year patient and renal survival rates were significantly higher in the fibrate-administered group than in control [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/5\" class=\"abstract_t\">5</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The effects of HMG-CoA reductase inhibitors (eg, statins) are controversial. Statins do not seem to lower urinary protein excretion, even in those with remission of dyslipidemia [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p/><p>The effects of plasmapheresis or LDL apheresis are uncertain [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/3\" class=\"abstract_t\">3</a>], but beneficial treatment with staphylococcal protein A immunoadsorption was reported as a pilot study from China [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/67\" class=\"abstract_t\">67</a>]. Protein A binds to the Fc receptor gamma chain (FcR gamma) of IgG [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/68\" class=\"abstract_t\">68</a>]. As noted above, deficiency of FcR gamma chains produces LPG-like lesions in mice independently of the apo E abnormality [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/41\" class=\"abstract_t\">41</a>]. Actually, the lack of LDL receptors [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/43\" class=\"abstract_t\">43</a>] and scavenger receptors [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/42\" class=\"abstract_t\">42</a>] due to FcR gamma deficiency may suppress the uptake lipoproteins and contribute to lipoprotein thrombi in the glomerulus. Thus, protein A immunoadsorption may be effective because dysfunction of FcR gamma may be important in the development of human LPG.</p><p>Another report showed that LDL apheresis using a heparin-induced extracorporeal lipoprotein precipitation system was successful because of lowering LDL cholesterol and triglycerides [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/69\" class=\"abstract_t\">69</a>].</p><p>The administration of glucocorticoids, immunosuppressant agents, <span class=\"nowrap\">and/or</span> anticoagulants are ineffective [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p>Despite the absence of published evidence, we suggest the use of lipid-lowering therapy. Our initial regimen consists of the administration of lipid-lowering agents, including a fibrate (eg, fenofibrate or <a href=\"topic.htm?path=bezafibrate-united-states-not-available-drug-information\" class=\"drug drug_general\">bezafibrate</a>). We subsequently monitor serum lipid levels and serum creatinine concentrations as well as urinary protein excretion. We aim for normalization of lipid levels, reduction of urinary protein excretion, and stabilization of the serum creatinine concentration.</p><p>If initial therapy is ineffective in sufficiently lowering proteinuria to goal levels by six months, we add angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) (see next section).</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Nonspecific therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no evidence that ACE inhibitors <span class=\"nowrap\">and/or</span> ARBs are effective in LPG. However, based upon their effectiveness in other forms of proteinuric chronic kidney disease, we recommend the administration of ACE inhibitors or ARBs both for blood pressure control and to slow progression of the renal disease among those with persistent proteinuria (which is defined as inadequate lowering of proteinuria to goal levels by six months from initiation of specific therapy).</p><p>The treatment goals with angiotensin inhibition are the same as those in other forms of proteinuric chronic kidney disease as described in the <span class=\"nowrap\">K/DOQI</span> guidelines (see <a href=\"topic.htm?path=antihypertensive-therapy-and-progression-of-nondiabetic-chronic-kidney-disease-in-adults\" class=\"medical medical_review\">&quot;Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults&quot;</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend a minimum reduction in protein excretion of at least 60 percent from baseline values, with goal protein excretion being less than 500 to 1000 <span class=\"nowrap\">mg/day</span>. Given simplicity and cost considerations, we initiate therapy with a single agent (either an ACE inhibitor or an ARB).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The goal blood pressure is the same as it is in other patients with proteinuric chronic kidney disease. (See <a href=\"topic.htm?path=antihypertensive-therapy-and-progression-of-nondiabetic-chronic-kidney-disease-in-adults\" class=\"medical medical_review\">&quot;Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Transplantation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>To date, five kidney transplants have been performed, and LPG has recurred in four transplanted allografts [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/15,48,58,70\" class=\"abstract_t\">15,48,58,70</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one case report, kidney function was lost within one year [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/58\" class=\"abstract_t\">58</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum creatinine levels reached approximately 2 <span class=\"nowrap\">mg/dL</span> (176.8 <span class=\"nowrap\">micromol/liter)</span> within four years in two cases [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/15,48\" class=\"abstract_t\">15,48</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One case revealed histologic recurrence one year after surgery [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/70\" class=\"abstract_t\">70</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The last case did not reveal any clinical features of recurrence of LPG after long-term follow-up [<a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/71\" class=\"abstract_t\">71</a>].</p><p/><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Dialysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no special selection between hemodialysis and peritoneal dialysis. However, hemodialysis appears to ameliorate the dyslipidemia in most cases.</p><p class=\"headingAnchor\" id=\"H588114218\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-glomerular-disease-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Glomerular disease in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lipoprotein glomerulopathy (LPG) is a rare and unique disorder of renal lipidosis. More than 150 cases of LPG have been reported worldwide, with most cases being found in Japan and East Asian countries. However, cases outside of Asia, such as the United States and Europe, have been identified. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H5\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LPG results from mutations in the <em>APOE</em> gene, with most mutations detected being found in <span class=\"nowrap\">and/or</span> around the low-density lipoprotein receptor binding domain. Although unproven, it is hypothesized that the abnormal lipoproteins aggregate and then deposit in the glomerular capillary walls <span class=\"nowrap\">and/or</span> around the mesangium, with subsequent transformation into lipoprotein thrombi. (See <a href=\"#H2\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>At presentation, most patients are asymptomatic and come to medical attention after the detection of proteinuria on routine screening examination. All patients with LPG have proteinuria of variable severity, ranging from mild to severe proteinuria. Most eventually develop nephrotic syndrome or nephrotic-range proteinuria. One-half of patients eventually develop end-stage renal disease. (See <a href=\"#H7\" class=\"local\">'Renal findings'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients also have hyperlipidemia with a predominance of triglycerides. Findings with ultracentrifugation and agarose gel electrophoresis are consistent with type III hyperlipoproteinemia. (See <a href=\"#H9\" class=\"local\">'Lipid and lipoprotein profiles'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Kidney biopsy reveals marked dilatation of the capillary lumen in the glomeruli by a pale-stained substance on light microscopy and, on electron microscopy, thrombus-like substances in the glomerular capillaries that are composed of granules and vacuoles of various sizes. These substances form concentric lamellate, like a fingerprint. (See <a href=\"#H10\" class=\"local\">'Histopathologic findings'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LPG is diagnosed in the patient with proteinuria, type III hyperlipoproteinemia with high levels of VLDL and IDL plus increased apo E concentration, and characteristic findings on renal biopsy. The diagnosis should be confirmed, if possible, with DNA sequence analysis of the <em>APOE</em> gene. (See <a href=\"#H15\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No effective therapeutic regimen has been established for LPG. We suggest the use of lipid lowering therapy including a fibrate (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We subsequently monitor serum lipid levels and creatinine concentrations, as well as urinary protein excretion. We aim for normalization of lipid levels, reduction of urinary protein excretion, and stabilization of serum creatinine concentration. (See <a href=\"#H18\" class=\"local\">'Specific therapies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with persistent proteinuria (&gt;500 to 1000 <span class=\"nowrap\">mg/day),</span> we recommend angiotensin inhibition with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). We initiate monotherapy and target a minimum reduction in protein excretion of at least 60 percent from baseline values, with goal protein excretion being less than 500 to 1000 <span class=\"nowrap\">mg/day</span>. (See <a href=\"#H19\" class=\"local\">'Nonspecific therapy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/1\" class=\"nounderline abstract_t\">Saito T, Sato H, Kudo K, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis 1989; 13:148.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/2\" class=\"nounderline abstract_t\">Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47:199.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/3\" class=\"nounderline abstract_t\">Saito T, Oikawa S, Sato H, Sasaki J. Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants. Nephron 1999; 83:193.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/4\" class=\"nounderline abstract_t\">Toyota K, Hashimoto T, Ogino D, et al. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy. J Hum Genet 2013; 58:254.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/5\" class=\"nounderline abstract_t\">Hu Z, Huang S, Wu Y, et al. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. Kidney Int 2014; 85:416.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/6\" class=\"nounderline abstract_t\">Oikawa S, Matsunaga A, Saito T, et al. Apolipoprotein E Sendai (arginine 145--&gt;proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol 1997; 8:820.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/7\" class=\"nounderline abstract_t\">Amatruda JM, Margolis S, Hutchins GM. Type 3 hyperlipoproteinemia with mesangial foam cells in renal glomeruli. Arch Pathol 1974; 98:51.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/8\" class=\"nounderline abstract_t\">Suzaki K, Kobori S, Ueno S, et al. Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis 1990; 80:181.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/9\" class=\"nounderline abstract_t\">Ellis D, Orchard TJ, Lombardozzi S, et al. Atypical hyperlipidemia and nephropathy associated with apolipoprotein E homozygosity. J Am Soc Nephrol 1995; 6:1170.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/10\" class=\"nounderline abstract_t\">Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy. Trends Cardiovasc Med 2002; 12:67.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/11\" class=\"nounderline abstract_t\">Chen S, Liu ZH, Zheng JM, et al. A complete genomic analysis of the apolipoprotein E gene in Chinese patients with lipoprotein glomerulopathy. J Nephrol 2007; 20:568.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/12\" class=\"nounderline abstract_t\">Matsunaga A, Sasaki J, Komatsu T, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int 1999; 56:421.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/13\" class=\"nounderline abstract_t\">Rovin BH, Roncone D, McKinley A, et al. APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. N Engl J Med 2007; 357:2522.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/14\" class=\"nounderline abstract_t\">Murano T, Matsumura R, Misawa Y, et al. Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg--&gt;Cys) from a patient with lipoprotein glomerulopathy. Metabolism 2002; 51:201.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/15\" class=\"nounderline abstract_t\">Foster K, Matsunaga A, Matalon R, et al. A rare cause of posttransplantation nephrotic syndrome. Am J Kidney Dis 2005; 45:1132.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/16\" class=\"nounderline abstract_t\">Cheung CY, Chan AO, Chan YH, et al. A rare cause of nephrotic syndrome: lipoprotein glomerulopathy. Hong Kong Med J 2009; 15:57.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/17\" class=\"nounderline abstract_t\">Han J, Pan Y, Chen Y, et al. Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China. Nephron Clin Pract 2010; 114:c260.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/18\" class=\"nounderline abstract_t\">Hagiwara M, Yamagata K, Matsunaga T, et al. A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy. Nephrol Dial Transplant 2008; 23:381.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/19\" class=\"nounderline abstract_t\">Kinomura M, Sugiyama H, Saito T, et al. A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant 2008; 23:751.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/20\" class=\"nounderline abstract_t\">Luo B, Huang F, Liu Q, et al. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy. Am J Nephrol 2008; 28:347.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/21\" class=\"nounderline abstract_t\">Bomback AS, Song H, D'Agati VD, et al. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy. Nephrol Dial Transplant 2010; 25:3442.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/22\" class=\"nounderline abstract_t\">Magistroni R, Bertolotti M, Furci L, et al. Lipoprotein glomerulopathy associated with a mutation in apolipoprotein e. Clin Med Insights Case Rep 2013; 6:189.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/23\" class=\"nounderline abstract_t\">Konishi K, Saruta T, Kuramochi S, et al. Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy. Nephron 1999; 83:214.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/24\" class=\"nounderline abstract_t\">Ando M, Sasaki J, Hua H, et al. A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int 1999; 56:1317.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/25\" class=\"nounderline abstract_t\">Ogawa T, Maruyama K, Hattori H, et al. A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol 2000; 14:149.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/26\" class=\"nounderline abstract_t\">Matsunaga A, Saito T. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia. Clin Exp Nephrol 2014; 18:220.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/27\" class=\"nounderline abstract_t\">Sam R, Wu H, Yue L, et al. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis 2006; 47:539.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/28\" class=\"nounderline abstract_t\">Mitani A, Ishigami M, Watase K, et al. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy. J Atheroscler Thromb 2011; 18:531.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/29\" class=\"nounderline abstract_t\">Tokura T, Itano S, Kobayashi S, et al. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy. J Atheroscler Thromb 2011; 18:536.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/30\" class=\"nounderline abstract_t\">Ishigaki Y, Oikawa S, Suzuki T, et al. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem 2000; 275:31269.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/31\" class=\"nounderline abstract_t\">Ishimura A, Watanabe M, Nakashima H, et al. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice. Clin Exp Nephrol 2009; 13:430.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/32\" class=\"nounderline abstract_t\">Hoffmann M, Scharnagl H, Panagiotou E, et al. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol 2001; 12:524.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/33\" class=\"nounderline abstract_t\">Janus ED, Grant S, Lintott CJ, Wardell MR. Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment. Atherosclerosis 1985; 57:249.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/34\" class=\"nounderline abstract_t\">Innerarity TL, Hui DY, Bersot TP, Mahley RW. Type III hyperlipoproteinemia: a focus on lipoprotein receptor-apolipoprotein E2 interactions. Adv Exp Med Biol 1986; 201:273.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/35\" class=\"nounderline abstract_t\">Ghiselli G, Gregg RE, Zech LA, et al. Phenotype study of apolipoprotein E isoforms in hyperlipoproteinaemic patients. Lancet 1982; 2:405.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/36\" class=\"nounderline abstract_t\">Wen M, Segerer S, Dantas M, et al. Renal injury in apolipoprotein E-deficient mice. Lab Invest 2002; 82:999.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/37\" class=\"nounderline abstract_t\">Langheinrich AC, Kampschulte M, Scheiter F, et al. Atherosclerosis, inflammation and lipoprotein glomerulopathy in kidneys of apoE-/-/LDL-/- double knockout mice. BMC Nephrol 2010; 11:18.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/38\" class=\"nounderline abstract_t\">Kiener PA, Rankin BM, Davis PM, et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol 1995; 15:990.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/39\" class=\"nounderline abstract_t\">Huang Y, Jaffa A, Koskinen S, et al. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol 1999; 19:1600.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/40\" class=\"nounderline abstract_t\">Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103:1194.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/41\" class=\"nounderline abstract_t\">Kanamaru Y, Nakao A, Shirato I, et al. Chronic graft-versus-host autoimmune disease in Fc receptor gamma chain-deficient mice results in lipoprotein glomerulopathy. J Am Soc Nephrol 2002; 13:1527.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/42\" class=\"nounderline abstract_t\">Miyahara Y, Nishimura S, Watanabe M, et al. Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy. Clin Exp Nephrol 2012; 16:115.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/43\" class=\"nounderline abstract_t\">Ito K, Nakashima H, Watanabe M, et al. Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities. Nephrol Dial Transplant 2012; 27:3899.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/44\" class=\"nounderline abstract_t\">Tavori H, Fan D, Giunzioni I, et al. Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice. J Lipid Res 2014; 55:2073.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/45\" class=\"nounderline abstract_t\">Saito T, Matsunaga A. Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis. Kidney Int 2014; 85:243.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/46\" class=\"nounderline abstract_t\">Zhang P, Matalon R, Kaplan L, et al. Lipoprotein glomerulopathy: first report in a Chinese male. Am J Kidney Dis 1994; 24:942.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/47\" class=\"nounderline abstract_t\">Meyrier A, Dairou F, Callard P, Mougenot B. Lipoprotein glomerulopathy: first case in a white European. Nephrol Dial Transplant 1995; 10:546.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/48\" class=\"nounderline abstract_t\">Mourad G, Djamali A, Turc-Baron C, Cristol JP. Lipoprotein glomerulopathy: a new cause of nephrotic syndrome after renal transplantation. Nephrol Dial Transplant 1998; 13:1292.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/49\" class=\"nounderline abstract_t\">Boumendjel R, Papari M, Gonzalez M. A rare case of lipoprotein glomerulopathy in a white man: an emerging entity in Asia, rare in the white population. Arch Pathol Lab Med 2010; 134:279.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/50\" class=\"nounderline abstract_t\">Sethi S. Renal failure with intracapillary thrombi. Lipoprotein glomerulopathy. Kidney Int 2008; 73:1097.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/51\" class=\"nounderline abstract_t\">Pasquariello A, Pasquariello G, Innocenti M, et al. Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. J Nephrol 2011; 24:381.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/52\" class=\"nounderline abstract_t\">Sipovskii VG, Klemina IK, Zverkov RV, et al. [A case of diagnosing lipoprotein glomerulopathy in Russia]. Arkh Patol 2016; 78:52.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/53\" class=\"nounderline abstract_t\">P&ecirc;gas KL, Rohde R, Garcia CD, et al. Lipoprotein glomerulopathy: a case report of a rare disease in a Brazilian child. J Bras Nefrol 2014; 36:93.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/54\" class=\"nounderline abstract_t\">Chang CF, Lin CC, Chen JY, et al. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3. Am J Kidney Dis 2003; 42:E18.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/55\" class=\"nounderline abstract_t\">Oikawa S, Suzuki N, Sakuma E, et al. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis 1991; 18:553.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/56\" class=\"nounderline abstract_t\">Hazzard WR, Porte D Jr, Bierman EL. Abnormal lipid composition of very low density lipoproteins in diagnosis of broad-beta disease (type 3 hyperlipoproteinemia). Metabolism 1972; 21:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/57\" class=\"nounderline abstract_t\">Fredrickson DS, Morganroth J, Levy RI. Type III hyperlipoproteinemia: an analysis of two contemporary definitions. Ann Intern Med 1975; 82:150.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/58\" class=\"nounderline abstract_t\">Saito T, Sato H, Oikawa S, et al. Lipoprotein glomerulopathy. Report of a normolipidemic case and review of the literature. Am J Nephrol 1993; 13:64.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/59\" class=\"nounderline abstract_t\">Saito T, Oikawa S, Sato H, et al. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features. Kidney Int Suppl 1999; 71:S37.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/60\" class=\"nounderline abstract_t\">Kawanishi K, Sawada A, Ochi A, et al. Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature. Case Rep Nephrol Urol 2013; 3:128.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/61\" class=\"nounderline abstract_t\">Amenomori M, Haneda M, Morikawa J, et al. A case of lipoprotein glomerulopathy successfully treated with probucol. Nephron 1994; 67:109.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/62\" class=\"nounderline abstract_t\">Sakatsume M, Kadomura M, Sakata I, et al. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity. Kidney Int 2001; 59:1911.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/63\" class=\"nounderline abstract_t\">Takasaki S, Maeda K, Joh K, et al. Macrophage Infiltration into the Glomeruli in Lipoprotein Glomerulopathy. Case Rep Nephrol Dial 2015; 5:204.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/64\" class=\"nounderline abstract_t\">Ieiri N, Hotta O, Taguma Y. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis 2003; 41:244.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/65\" class=\"nounderline abstract_t\">Arai T, Yamashita S, Yamane M, et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis 2003; 169:293.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/66\" class=\"nounderline abstract_t\">Matsunaga A, Furuyama M, Hashimoto T, et al. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin Exp Nephrol 2009; 13:659.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/67\" class=\"nounderline abstract_t\">Xin Z, Zhihong L, Shijun L, et al. Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: a pilot study. Nephrol Dial Transplant 2009; 24:864.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/68\" class=\"nounderline abstract_t\">Atkins KL, Burman JD, Chamberlain ES, et al. S. aureus IgG-binding proteins SpA and Sbi: host specificity and mechanisms of immune complex formation. Mol Immunol 2008; 45:1600.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/69\" class=\"nounderline abstract_t\">Russi G, Furci L, Leonelli M, et al. Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report. J Med Case Rep 2009; 3:9311.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/70\" class=\"nounderline abstract_t\">Miyata T, Sugiyama S, Nangaku M, et al. Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney. J Am Soc Nephrol 1999; 10:1590.</a></li><li><a href=\"https://www.uptodate.com/contents/lipoprotein-glomerulopathy/abstract/71\" class=\"nounderline abstract_t\">Cheung CY, Chan AO, Chan GP, et al. Long-term outcome of kidney transplantation in a patient with coexisting lipoprotein glomerulopathy and fibrillary glomerulonephritis. Clin Kidney J 2014; 7:396.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3088 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOGENESIS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">APOE variants</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Role of other factors</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">EPIDEMIOLOGY</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL FEATURES</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Renal findings</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Non-renal manifestations</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Lipid and lipoprotein profiles</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Histopathologic findings</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">- Light microscopy</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- Electron microscopy</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">- Confirmation of lipoprotein deposits</a></li></ul></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">EVALUATION</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">DIAGNOSIS</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">THERAPY</a><ul><li><a href=\"#H18\" id=\"outline-link-H18\">Specific therapies</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Nonspecific therapy</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Transplantation</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Dialysis</a></li></ul></li><li><a href=\"#H588114218\" id=\"outline-link-H588114218\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEPH/3088|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=NEPH/59528\" class=\"graphic graphic_algorithm\">- Pathogenesis of LPG</a></li></ul></li><li><div id=\"NEPH/3088|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=NEPH/70954\" class=\"graphic graphic_figure\">- ApoE mutations</a></li><li><a href=\"image.htm?imageKey=NEPH/105284\" class=\"graphic graphic_figure\">- Location of lipoprotein glomerulopathy cases by genotype</a></li></ul></li><li><div id=\"NEPH/3088|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=NEPH/65560\" class=\"graphic graphic_picture\">- Light microscopy kid LPG</a></li><li><a href=\"image.htm?imageKey=NEPH/62285\" class=\"graphic graphic_picture\">- Electron micro kid LPG</a></li><li><a href=\"image.htm?imageKey=NEPH/74959\" class=\"graphic graphic_picture\">- IF for apoE kid LPG</a></li><li><a href=\"image.htm?imageKey=NEPH/68230\" class=\"graphic graphic_picture\">- Oil redO stain kid LPG</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antihypertensive-therapy-and-progression-of-nondiabetic-chronic-kidney-disease-in-adults\" class=\"medical medical_review\">Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glomerular-disease-evaluation-and-differential-diagnosis-in-adults\" class=\"medical medical_review\">Glomerular disease: Evaluation and differential diagnosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypertriglyceridemia\" class=\"medical medical_review\">Hypertriglyceridemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-glomerular-disease-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Glomerular disease in adults</a></li></ul></div></div>","javascript":null}